Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome

20108 citationsJournal Article

Authors

Harold Bays · Louisville Metabolic and Atherosclerosis Research Center

Arvind Shah · Merck & Co., Inc., Rahway, NJ, USA (United States)

Geraldine Macdonell · Merck & Co., Inc., Rahway, NJ, USA (United States)

William Taggart · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome.

Topics & Keywords

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Metabolic Syndrome and Related Disorders

Volume 9, Issue 2, pp. 135-142

DOI: 10.1089/met.2010.0068

Field-Weighted Citation Impact: 1.19